Millennium Management’s Akero Therapeutics AKRO Stock Holding History

Millennium Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-30,000	Closed	-$1.21M	–	5822
2025 Q1	$1.21M	Buy	+30,000	New	+$1.27M	﹤0.01%	4211
2024 Q2	–	Sell	-20,400	Closed	-$515K	–	5823
2024 Q1	$515K	Buy	+20,400	New	+$490K	﹤0.01%	4791
2023 Q4	–	Sell	-36,200	Closed	-$1.83M	–	6030
2023 Q3	$1.83M	Buy	+36,200	New	+$1.69M	﹤0.01%	3639

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Millennium Management's AKRO Position: Q4 2025 in Review

Millennium Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 20,197 shares — an estimated $959K sold.

Millennium Management first reported a position in AKRO in Q2 2019 and held it in 21 quarters. The position peaked at $20M in Q1 2024. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Millennium Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Millennium Management sold 20,197 Akero Therapeutics shares in Q4 2025, an estimated $959K.
Millennium Management first reported a position in Akero Therapeutics in Q2 2019 and held it in 21 quarters.
Millennium Management's Akero Therapeutics position peaked at $20M in Q1 2024.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Millennium Management's 13F filing for Q4 2025, filed 17 Feb 2026.